Enrollment in global Phase 3 HARBORTM study for del-desiran in DM1 is on track Avidity initiated biomarker cohort for del-brax FORTITUDETM study for FSHD; pursuing a potential accelerated approval path for del-brax Reported positive del-zota data from Phase 1/2 EXPLORE44TM trial for DMD44 Avidity to provide a first look at precision cardiology candidates and a glimpse at next-generation technology innovations via webcast event November 12, 2024 SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA ), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCsTM), today reported financial results for the third quarter ended September 30, 2024 , and highlighted recent corporate progress.
"We are executing three potentially registrational clinical trials in three rare diseases where there are limited or no therapeutic options available. We reported positive del-zota data from the 5 mg/kg cohort of our Phase 1/2 EXPLORE44TM trial for DMD44 and have initiated enrollment in the EXPLORE44-OLETM. In addition, enrollment is on track for del-desiran's global Phase 3 HARBORTM trial in DM1 and we initiated the biomarker cohort of our FORTITUDETM study in FSHD, marking a key step in our strategy to pursue a potential accelerated approval path for del-brax," said Sarah Boyce , president and chief executive officer at Avidity.
"As we build for the future, we look forward to sharing our excitin.
